Health TrialsbyHealthPanel

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS-05)

This phase II study is a prospective, multi-center, double-blinded, and randomized trial to compare the efficacy and safety of perioperative SOX plus serplulimab with SOX plus placebo for locally advanced gastric adenocarcinoma with proficient mismatch repair

Participants needed: 314
Trial details
Phase: Phase 2Age: 18-80Biological sex: AllType: InterventionalSponsor: Yu jirenUpdated: Jan 17, 2024Locations: 5
Eligibility criteria

Voluntary participation in the clinical study; fully understands and is informed... [+8]

HER2-positive, EBER-positive or dMMR. [+16]

Read more
Status: Not yet recruiting

Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

This study is a prospective, single arm, multi-center phase II clinical trial designed to evaluate the efficacy and safety of perioperative SOX combined with toripalimab in participants with Epstein-Barr Virus-associated locally advanced gastric or esophagogastric junction adenocarcinoma.

Participants needed: 30
Trial details
Phase: Phase 2Age: 18-80Biological sex: AllType: InterventionalSponsor: Yu jirenUpdated: Aug 1, 2023Locations: 8
Eligibility criteria

Voluntary participation in the clinical study; fully understands and is informed... [+17]

HER2-positive status defined as either IHC score of 3+ or IHC 2+ with amplificat... [+16]

Read more
Status: Recruiting

Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

This study is a prospective, multi-center, randomized controlled phase II trial to compare the efficacy of perioperative SOX plus toripalimab, toripalimab monotherapy with SOX regimen in participants with dMMR locally advanced gastric or esophagogastric junction adenocarcinoma

Participants needed: 90
Trial details
Phase: Phase 2Age: 18-80Biological sex: AllType: InterventionalSponsor: Yu jirenUpdated: Jul 25, 2023Locations: 8
Eligibility criteria

Voluntary participation in the clinical study; fully understands and is informed... [+14]

HER2-positive status defined as either IHC score of 3+ or IHC 2+ with amplificat... [+16]

Read more